Omnicell, Inc. (OMCL) Given Average Rating of “Buy” by Brokerages


Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Buy” from the twelve brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $77.13.

OMCL has been the subject of several research reports. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Piper Jaffray Companies reiterated a “neutral” rating and issued a $70.00 target price on shares of Omnicell in a research report on Friday, February 8th. They noted that the move was a valuation call. Cantor Fitzgerald reiterated an “overweight” rating and issued a $80.00 target price (up previously from $70.00) on shares of Omnicell in a research report on Thursday, December 6th. Zacks Investment Research lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, Dougherty & Co lifted their target price on Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday.


Get Omnicell alerts:

In related news, insider Joseph Brian Spears sold 9,346 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $85.10, for a total transaction of $795,344.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter J. Kuipers sold 2,429 shares of the business’s stock in a transaction that occurred on Tuesday, December 18th. The shares were sold at an average price of $64.18, for a total value of $155,893.22. Following the transaction, the insider now owns 47,814 shares of the company’s stock, valued at approximately $3,068,702.52. The disclosure for this sale can be found here. Insiders have sold a total of 58,400 shares of company stock valued at $4,393,736 in the last 90 days. Insiders own 3.71% of the company’s stock.


A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new position in Omnicell during the 4th quarter worth $35,000. Bronfman E.L. Rothschild L.P. boosted its position in Omnicell by 451.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock worth $38,000 after acquiring an additional 506 shares during the period. IFP Advisors Inc boosted its position in Omnicell by 109.3% during the 4th quarter. IFP Advisors Inc now owns 741 shares of the company’s stock worth $45,000 after acquiring an additional 387 shares during the period. First Hawaiian Bank boosted its position in Omnicell by 121.2% during the 4th quarter. First Hawaiian Bank now owns 1,369 shares of the company’s stock worth $84,000 after acquiring an additional 750 shares during the period. Finally, Private Capital Group LLC boosted its position in Omnicell by 14.9% during the 4th quarter. Private Capital Group LLC now owns 1,390 shares of the company’s stock worth $85,000 after acquiring an additional 180 shares during the period. Institutional investors and hedge funds own 99.89% of the company’s stock.


Shares of OMCL traded up $0.31 during mid-day trading on Wednesday, hitting $83.66. The stock had a trading volume of 12,821 shares, compared to its average volume of 345,625. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 54.69, a PEG ratio of 4.01 and a beta of 1.18. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. Omnicell has a fifty-two week low of $41.59 and a fifty-two week high of $86.87.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 7th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.54 by $0.16. The company had revenue of $211.75 million during the quarter, compared to analyst estimates of $215.41 million. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 EPS. On average, sell-side analysts predict that Omnicell will post 1.83 earnings per share for the current fiscal year.


About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Read More: Swap

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Leave a Reply

Your email address will not be published.